ATE462787T1 - Reversibles sirna-silencing eines mutierten und endogenen huntington-wildtypgens und dessen anwendung zur behandlung von morbus huntington - Google Patents
Reversibles sirna-silencing eines mutierten und endogenen huntington-wildtypgens und dessen anwendung zur behandlung von morbus huntingtonInfo
- Publication number
- ATE462787T1 ATE462787T1 AT07290751T AT07290751T ATE462787T1 AT E462787 T1 ATE462787 T1 AT E462787T1 AT 07290751 T AT07290751 T AT 07290751T AT 07290751 T AT07290751 T AT 07290751T AT E462787 T1 ATE462787 T1 AT E462787T1
- Authority
- AT
- Austria
- Prior art keywords
- huntington
- disease
- treatment
- application
- type
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07290751A EP2014769B1 (de) | 2007-06-18 | 2007-06-18 | Reversibles siRNA-Silencing eines mutierten und endogenen Huntington-Wildtypgens und dessen Anwendung zur Behandlung von Morbus Huntington |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE462787T1 true ATE462787T1 (de) | 2010-04-15 |
Family
ID=38476952
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT07290751T ATE462787T1 (de) | 2007-06-18 | 2007-06-18 | Reversibles sirna-silencing eines mutierten und endogenen huntington-wildtypgens und dessen anwendung zur behandlung von morbus huntington |
Country Status (7)
Country | Link |
---|---|
US (1) | US8217018B2 (de) |
EP (1) | EP2014769B1 (de) |
JP (1) | JP5401451B2 (de) |
AT (1) | ATE462787T1 (de) |
CA (1) | CA2690730C (de) |
DE (1) | DE602007005629D1 (de) |
WO (1) | WO2009007855A2 (de) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8679750B2 (en) * | 2008-05-09 | 2014-03-25 | The University Of British Columbia | Methods and compositions for the treatment of Huntington'S disease |
WO2009135322A1 (en) * | 2008-05-09 | 2009-11-12 | The Universtity Of British Columbia | Methods and compositions for the treatment of huntington's disease |
CN102282155B (zh) | 2008-12-02 | 2017-06-09 | 日本波涛生命科学公司 | 磷原子修饰的核酸的合成方法 |
US9744183B2 (en) | 2009-07-06 | 2017-08-29 | Wave Life Sciences Ltd. | Nucleic acid prodrugs and methods of use thereof |
CA2789005A1 (en) | 2010-02-08 | 2011-08-11 | Isis Pharmaceuticals, Inc. | Selective reduction of allelic variants |
JP6018506B2 (ja) | 2010-02-08 | 2016-11-02 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | 対立遺伝子多様体の選択的低減 |
US20130109048A1 (en) * | 2010-07-09 | 2013-05-02 | Ecole Polytechnique Federale De Lausanne (Epfl) | Method for in-vitro monitoring of neuronal disorders and use thereof |
DK2620428T3 (da) | 2010-09-24 | 2019-07-01 | Wave Life Sciences Ltd | Asymmetrisk hjælpegruppe |
DK2734208T3 (en) | 2011-07-19 | 2017-06-19 | Wave Life Sciences Ltd | PROCEDURES FOR SYNTHESIS OF FUNCTIONALIZED NUCLEIC ACIDS |
WO2013022966A1 (en) | 2011-08-11 | 2013-02-14 | Isis Pharmaceuticals, Inc. | Linkage modified gapped oligomeric compounds and uses thereof |
WO2013130824A1 (en) | 2012-02-29 | 2013-09-06 | Sangamo Biosciences, Inc. | Methods and compositions for treating huntington's disease |
RU2015104762A (ru) | 2012-07-13 | 2018-08-31 | Уэйв Лайф Сайенсес Лтд. | Хиральный контроль |
CN104684923B (zh) | 2012-07-13 | 2018-09-28 | 株式会社新日本科学 | 手性核酸佐剂 |
EP2872485B1 (de) | 2012-07-13 | 2020-12-16 | Wave Life Sciences Ltd. | Asymmetrische hilfsgruppe |
EP2906258A4 (de) * | 2012-10-15 | 2016-08-10 | Ionis Pharmaceuticals Inc | Zusammensetzungen zur modulierung der c9orf72-expression |
EP2906697A4 (de) | 2012-10-15 | 2016-06-22 | Ionis Pharmaceuticals Inc | Verfahren zur überwachung der c9orf72-expression |
SG11201507496UA (en) | 2013-04-17 | 2015-11-27 | Pfizer | N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases |
WO2015054676A2 (en) | 2013-10-11 | 2015-04-16 | Isis Pharmaceuticals, Inc. | Compositions for modulating c9orf72 expression |
JP2016537341A (ja) * | 2013-11-11 | 2016-12-01 | サンガモ バイオサイエンシーズ, インコーポレイテッド | ハンチントン病を処置するための方法および組成物 |
WO2015108048A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
JPWO2015108047A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
US10322173B2 (en) | 2014-01-15 | 2019-06-18 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
PT3094728T (pt) | 2014-01-16 | 2022-05-19 | Wave Life Sciences Ltd | Desenho quiral |
AU2015255877B2 (en) * | 2014-05-08 | 2020-03-26 | Chdi Foundation, Inc. | Methods and compositions for treating huntington's disease |
SG11201708468YA (en) | 2015-04-16 | 2017-11-29 | Ionis Pharmaceuticals Inc | Compositions for modulating c9orf72 expression |
MA43072A (fr) | 2015-07-22 | 2018-05-30 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
WO2017079291A1 (en) | 2015-11-02 | 2017-05-11 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating c90rf72 |
MA45270A (fr) | 2016-05-04 | 2017-11-09 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
-
2007
- 2007-06-18 EP EP07290751A patent/EP2014769B1/de not_active Not-in-force
- 2007-06-18 DE DE602007005629T patent/DE602007005629D1/de active Active
- 2007-06-18 AT AT07290751T patent/ATE462787T1/de not_active IP Right Cessation
-
2008
- 2008-06-18 CA CA2690730A patent/CA2690730C/en not_active Expired - Fee Related
- 2008-06-18 JP JP2010512808A patent/JP5401451B2/ja not_active Expired - Fee Related
- 2008-06-18 US US12/665,137 patent/US8217018B2/en not_active Expired - Fee Related
- 2008-06-18 WO PCT/IB2008/002603 patent/WO2009007855A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
DE602007005629D1 (de) | 2010-05-12 |
JP5401451B2 (ja) | 2014-01-29 |
CA2690730A1 (en) | 2009-01-15 |
US20100299768A1 (en) | 2010-11-25 |
CA2690730C (en) | 2018-07-31 |
WO2009007855A3 (en) | 2009-04-02 |
EP2014769B1 (de) | 2010-03-31 |
EP2014769A1 (de) | 2009-01-14 |
JP2010530239A (ja) | 2010-09-09 |
WO2009007855A2 (en) | 2009-01-15 |
US8217018B2 (en) | 2012-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE462787T1 (de) | Reversibles sirna-silencing eines mutierten und endogenen huntington-wildtypgens und dessen anwendung zur behandlung von morbus huntington | |
HK1118577A1 (en) | Rnai expression constructs rnai | |
ATE521711T1 (de) | In-vivo-screening-modelle zur behandlung der alzheimer-krankheit und anderer erkrankungen in zusammenhang mit dem qpct-gen | |
PT2257155T (pt) | Criopreservação de células e tecidos biológicos | |
EP3839050A3 (de) | Disruptionsfreies gen-targeting | |
WO2010017562A3 (en) | Induced pluripotent stem cells | |
WO2007035213A3 (en) | Transgenic ungulates expressing ctla4-ig and uses thereof | |
WO2010124200A3 (en) | Genetically modified rat models for cancer | |
IN2009DN07390A (de) | ||
GB2462764A (en) | Ex vivo methods for validating substance testing with human organs and or tissues | |
WO2007064846A3 (en) | COMPOSITIONS AND METHODS OF USING siRNA TO KNOCKDOWN GENE EXPRESSION AND TO IMPROVE SOLID ORGAN AND CELL TRANSPLANTATION | |
EP2641911A3 (de) | Zusammensetzungen und Verfahren zur Neuprogrammierung von Zellen ohne genetische Modifikation | |
EP1874922A4 (de) | Verfahren zur verwendung von stromazellen aus nabelschnurblut zum expandieren und einpflanzen von kernhaltigen zellen aus nabelschnurblut | |
FR2934943B1 (fr) | Utilisation d'apiogalacturonanes et de ses derives pour la stimulation des reactions de defense et de resistance des plantes contre le stress biotiques et abiotiques | |
WO2011097181A3 (en) | Compositions and methods for re-programming cells without genetic modification for treatment of neurological disorders | |
FR2917975B1 (fr) | Compositions et traitement de l'insuffisance cardiaque chez les animaux mammiferes non humains | |
WO2009047809A3 (en) | Sequence variants for inferring human pigmentation patterns | |
WO2011156734A3 (en) | Method of characterizing vascular diseases | |
BR112013007041A2 (pt) | animal não humano, descendente, linhagem de células, tecido, explante de órgão, ou cultura dos mesmos, uso do modelo de doenças inflamatórias e métodos para o rastreio de compostos anti-inflamatórios e para a avaliação | |
WO2008099280A3 (en) | Regulation of expression of pi3kb protein in tumors | |
ATE513929T1 (de) | Gene mit einfluss auf die menschliche gedächtnisleistung | |
WO2009102366A3 (en) | Expression of orphan gpr64 in inflammatory diseases | |
ATE516496T1 (de) | Verfahren zur in-vivo-suche nach kardiotoxischen substanzen mit teleost | |
GB0820397D0 (en) | Cells, nucleic acid constructs, cells comprising said constructs and methods utilizing said cells in the treatment of diseases | |
WO2010059558A3 (en) | Plant defense genes and proteins and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |